WEBULL
WebtradeDownload

CRISPR Therapeutics (CRSP) Stock Looks Fully Priced Despite Stronger Pipeline Data

Simply Wall St · 1d ago

CRISPR Therapeutics stock has climbed back into positive territory over the past few years, yet the valuation read is still not straightforward for a gene editing specialist that has seen its share price fall sharply over a five year window. With the market treating the company as overvalued on traditional multiples and the broader checks sending a mixed signal, investors face a pricing puzzle rather than a clear bargain.

  • Over the last 5 years, CRISPR Therapeutics shares have declined about 52%, which leaves long term holders with losses even after the more recent recovery.
  • Fresh Phase 1a data for CTX310 on ANGPTL3 editing can support higher expectations for the pipeline. However, the inherent clinical and regulatory risk in gene editing may cap how much investors are willing to pay up for that potential.
  • With a value score of 3, the stock screens as a mixed picture rather than clearly cheap or clearly expensive on the wider valuation checks.

The issue now is whether CRISPR Therapeutics justifies this pricing reset after a difficult five year stretch, or whether the current level already bakes in most of the realistic upside.

Scan beyond CRISPR Therapeutics and see how other gene and biotech plays with stronger balance sheets and cash flows line up in our hand picked solid balance sheet and fundamentals stocks screener (24 results)

Has CRISPR Therapeutics Run Too Far on Book Value?

P/B is usually a cleaner lens for a pre profit biotech like CRISPR Therapeutics because the balance sheet and cash pile matter more than near term earnings. On this yardstick, CRISPR Therapeutics trades at about 3.1x book value, which is above the Biotechs sector average of roughly 2.5x and also well below the peer group average of about 12.2x.

The stock therefore carries a premium to the broader industry while still sitting at a sizeable discount to higher priced gene editing and biotech peers. Despite the recent CTX310 data helping sentiment, the current P/B level still implies that investors are paying up versus the typical biotech for CRISPR Therapeutics and its pipeline risk profile.

On the P/B yardstick alone, CRISPR Therapeutics looks overvalued relative to the wider Biotechs sector even if it screens cheaper than many direct peers.

NasdaqGM:CRSP P/B Ratio as at Sep 2026
NasdaqGM:CRSP P/B Ratio as at Sep 2026

See what the numbers say about this price — find out in our valuation breakdown.

The CRISPR Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this CRISPR Therapeutics valuation puzzle leaves off. They spell out what mix of future growth, profitability and earnings power would need to play out for CRISPR Therapeutics' shares to be worth materially more or materially less than the current price. Each narrative focuses on the assumptions sitting behind its fair value view so you can track those against the actual numbers as results arrive.

Share a CRISPR Therapeutics Narrative to be one of the early voices in the Simply Wall St community, putting a number driven case on whether CTX310's ANGPTL3 editing data ultimately supports today's valuation. Add your view now so you can track how your thesis holds up as fresh trial readouts and market reactions arrive.

Do you think there's more to the story for CRISPR Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

CRISPR Therapeutics now screens as overvalued on traditional market multiples, with the current P/B suggesting investors already assign a premium to its cash and pipeline relative to the broader biotech group. That premium rests on confidence that CTX310 and the wider gene editing portfolio eventually justify paying more for each dollar of book value. The key debate from here is whether the science converts into a business with cash flows strong enough to support that richer multiple, or whether the sector level valuation gap reflects the market correctly pricing the clinical and regulatory risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.